Results 201 to 210 of about 1,640,993 (346)

[Analysis of Risk Factors of Chronic Pulmonary Heart Disease in Patients With Pneumoconiosis]. [PDF]

open access: yesSichuan Da Xue Xue Bao Yi Xue Ban
Chen Q   +9 more
europepmc   +1 more source

Pulmonary hypertension in congenital heart disease of children

open access: diamond
Radohery Lovasoa Randriamanga   +2 more
openalex   +2 more sources

The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease.

open access: yesJACC. Heart failure, 2015
Emmanouil Tampakakis   +8 more
semanticscholar   +1 more source

CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target

open access: yesAdvanced Science, EarlyView.
This review conceptualizes CD147 as a fundamental “Energy‐Structure Coupler,” physically bridging metabolic flux (via MCTs) with morphogenetic plasticity (via integrins/MMPs) to drive cancer, infection, and autoimmunity. Addressing the “specificity paradox” that limits current translation, the authors chart a strategic roadmap—spanning logic‐gated ...
Xiang‐Min Yang   +2 more
wiley   +1 more source

Home-based telerehabilitation in older patients with chronic obstructive pulmonary disease and heart failure: a randomised controlled trial [PDF]

open access: bronze, 2017
Palmira Bernocchi   +9 more
openalex   +1 more source

Macrophage–Derived Ferritin Exacerbates Silica‐Induced Pulmonary Fibrosis via PIK3R2‐Mediated Fibroblast Differentiation

open access: yesAdvanced Science, EarlyView.
This study identifies ferritin as a pivotal mediator of silica‐induced pulmonary fibrosis. Macrophage‐derived ferritin drives fibroblast‐to‐myofibroblast differentiation via the PIK3R2/SMAD pathway, while ferritin knockdown alleviates fibrosis. These findings define ferritin as both a biomarker and pathogenic driver, highlighting ferritin‐PIK3R2 ...
Liqun Wang   +14 more
wiley   +1 more source

Pulmonary hypertension associated with congenital heart disease; clinical decision scenario

open access: gold, 2020
Ali A. Alakhfash   +4 more
openalex   +1 more source

Pro‐ATO/Allicin Liposomes for Dual‐Pathway Targeting of p53‐Mutant Tumors

open access: yesAdvanced Science, EarlyView.
Schematic illustration of the “pro‐ATO”/allicin liposomal strategy. Liposomal encapsulation improves the stability and bioavailability of both agents while masking allicin's odor. Upon release in the tumor microenvironment, ATO reactivates structural p53 mutants, and allicin inhibits ATR signaling while releasing H2S, collectively inducing synthetic ...
Xiaoling Xu   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy